PTC124

DRUG3 trials

Sponsors

PTC Therapeutics

Conditions

Cystic FibrosisDuchenne Muscular Dystrophy

Phase 2

PTC124 for Cystic Fibrosis

CompletedNCT00234663

PTC TherapeuticsCystic Fibrosis

Start: 2005-09-30End: 2006-08-31Target: 24Updated: 2009-01-13

Safety and Efficacy Study of PTC124 in Duchenne Muscular Dystrophy

CompletedNCT00264888

PTC TherapeuticsDuchenne Muscular Dystrophy

Start: 2005-12-31End: 2007-05-31Target: 38Updated: 2009-01-14

PTC124 for the Treatment of Cystic Fibrosis

CompletedNCT00351078

PTC TherapeuticsCystic Fibrosis

Start: 2006-12-31End: 2007-07-31Updated: 2017-12-13

Related Papers

Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients

Journal of Comparative Effectiveness Research2021-11-1857 citations

Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study

Journal of Comparative Effectiveness Research2020-01-30124 citations

Phase 2a Study of Ataluren-Mediated Dystrophin Production in Patients with Nonsense Mutation Duchenne Muscular Dystrophy

PLoS ONE2013-12-11241 citations